Illumina connects genomic AI with sequencing-data analysis

Illumina embeds AI in the path from sequencing data to interpretable genomic outputs. DRAGEN is a concrete example: a secondary-analysis engine whose deployment, version and licensing choices affect both the scientific workflow and the cost of running it.

01 / ProductAI supports several stages of the genomic workflow

Illumina supplies sequencing technology and analysis software. Its AI overview describes separate roles for variant calling, variant prioritisation and predictions about genomic changes. These are different analytical tasks. A system that identifies a candidate variant is not, merely by doing so, establishing its biological significance or making a patient-level decision.

DRAGEN focuses on secondary analysis: processing sequencing data into structured outputs such as variant calls and associated quality information. Its current description includes machine-learning methods alongside alignment, noise modelling and other analytical operations. This makes AI part of a defined bioinformatics pipeline, rather than a replacement for the entire laboratory or interpretation process.

Illumina connects those outputs with other software in its BioInsight ecosystem, including downstream analysis tools. For a buyer, the practical question is which boundary is being changed. Replacing a secondary-analysis pipeline, adopting an interpretation application and buying sequencing capacity are related but separate decisions, each with its own inputs, validation work and commercial terms.

02 / AudienceA fit for laboratories that can define their analytical contract

A research team producing repeatable sequencing runs can evaluate DRAGEN against a specific pipeline requirement: supported assay, input format, reference resources, variant classes and output files. A precise contract makes comparison possible. A broad request for the most accurate genomic AI does not specify the data or errors that matter to the study.

Large cohorts also make consistency important. A change in software, reference or configuration can alter outputs across samples. The team needs a policy for when to reprocess earlier data and how to identify results produced by different methods. Standardisation is therefore an operational decision as well as a computational one.

Deep Genomics provides a research comparison for biological foundation models and genetic-medicine discovery. Tempus provides a different context around multimodal data and healthcare applications. DRAGEN's secondary-analysis role should be evaluated on its own terms; neither a platform partnership nor a broad ecosystem claim establishes interchangeability between those offers.

03 / WorkflowProposed workflow: compare a pinned analysis on representative samples

Consider a proposed research project moving a defined germline analysis onto DRAGEN. Start by documenting the current pipeline, assay and accepted output format. Choose reference samples and representative difficult cases before running comparisons. Include the regions and variant classes that matter to the research question, rather than relying only on a single overall concordance number.

Select a deployment using the official options. Illumina describes dedicated servers, managed cloud, bring-your-own-licence cloud, standard CPU infrastructure and supported onboard instrument analysis. The relevant choice is where data can be processed, who operates the compute and which exact pipeline is available there. Avoid assuming every onboard application mirrors every server capability.

Pin the software release, reference resources and configuration, then run the candidate analysis against the established comparison set. Examine disagreements by variant class and genomic context. A difference is a finding to investigate, not automatically an error by either pipeline. Keep the original reads, quality information and evidence needed for an analyst to understand the disagreement.

Next test the operational path: submitting a sample, retrieving outputs, handling a failed run and reconnecting results with the sample record. Establish which identifiers travel through each system. A scientifically sound result assigned to the wrong sample is still an unusable output, so this part of the evaluation belongs alongside variant-level comparison.

Finally assess a batch at the intended scale and record compute, storage, analysis licensing and analyst effort separately. Confirm how the workflow behaves when a resource limit or licence problem interrupts processing. This is a proposed validation approach, not a claim that Sequenced has processed genomic samples or reproduced Illumina's published accuracy or runtime figures.

04 / PricingPricing depends on version, sample and deployment

The pricing details describe per-sample pricing for DRAGEN v4.6 and later on selected BioInsight Connected deployments, alongside displayed analysis tiers. For a complete germline Genome run, the table lists 10, 12 and 15 BioInsight Credits for Foundation, Advanced and Comprehensive respectively. Illumina states a US list conversion of one credit to US$1; local purchase terms can differ. Compute, storage and other infrastructure charges are excluded.

There is an important version qualification on the same pricing page: a note directly beneath the germline pipeline table says tiered pricing takes effect with DRAGEN v4.7, although the overall page describes connected pricing from v4.6. The note does not clearly identify a narrower germline pipeline scope. Treat the displayed rates as a reference and obtain confirmation of the effective tier for the exact pipeline and version; they are not an unconditional v4.6 entitlement schedule.

The licensing reference is essential to interpreting that table. Dedicated DRAGEN Server licences and legacy cloud FPGA credentials can retain prepaid gigabase metering, while supported onboard analysis is included with the instrument and not metered. Do not apply the new per-sample table to every deployment simply because it runs a recent DRAGEN release.

The migration guide adds a deadline for public-cloud BYOL customers: legacy prepaid gigabase licences can be purchased or renewed until 31 March 2027. Existing negotiated agreements continue to the end of their term, and qualifying purchases keep their remaining quota for the agreed period. This deadline concerns public-cloud BYOL; it should not be applied to every DRAGEN Server licence.

For a budget, first classify the planned sample and analysis correctly, then obtain the applicable credit purchase terms or legacy licence quote. Include data movement, retained outputs, reruns and the compute environment. The most useful comparison is cost per accepted research result under a defined workflow. A lower software charge can be outweighed by infrastructure or repeated processing that a headline tariff does not describe.

Keep the cost estimate tied to a sample manifest and a named analysis configuration. This makes a later invoice discrepancy investigable: the team can distinguish a changed assay classification from an extra run or a different set of requested outputs.

05 / DistinctionsDeployment flexibility can separate scientific and infrastructure choices

The deployment page describes ways to use DRAGEN on both specialised and standard compute. That gives a laboratory a practical question to investigate: whether it can retain a consistent analytical method while choosing infrastructure that fits its data policy and workload. Illumina's concordance claims should still be checked for the exact release and configuration used in a migration.

The AI overview also distinguishes calling from downstream prioritisation. This is useful for designing a review boundary. A variant list can be generated through a reproducible computational process while the relevance of individual findings remains a separate evidence assessment. Keep those stages visible in both the software design and the language used to describe results.

A broad supported pipeline portfolio may reduce the number of separately maintained tools, but it does not remove application-specific evaluation. Germline, somatic and nonhuman workflows ask different questions of their data. Treat a successful evaluation of one workflow as evidence for that workflow, then scope any extension deliberately rather than generalising a single pilot across the laboratory.

06 / QuestionsConnected licensing and research-use boundaries need explicit treatment

The licensing documentation says connected runs report operational information including version, status, duration, licensing consumed and run metadata. Local processing should therefore not be described as wholly disconnected merely because genomic data remain in the organisation's environment. Ask the infrastructure team to review the actual licensing connection and the information it sends.

The reviewed DRAGEN product and deployment pages specify research use, not diagnostic procedures. This blueprint does not establish clinical authorisation or recommend patient-specific interpretation. A laboratory with a clinical requirement needs to resolve the applicable validated product, workflow and jurisdiction independently of a general research-software description.

Version changes also deserve a scientific release process. Improvements described by a vendor can change which results are produced, and a new commercial model can change which capabilities are economical to run. Review analytical differences and licensing effects together before an upgrade. Preserve the ability to explain which method produced an older result even after the production environment has moved forward.

07 / DecisionChoose a reproducible analysis and price its real operating mode

Illumina is a prominent AI-related company with concrete software at the sequencing-analysis boundary. DRAGEN is worth evaluating when a research team can name its assay, outputs and validation criteria. The strongest decision combines representative analytical evidence with a deployment-specific cost model and a clear downstream review process, rather than relying on a single benchmark or credit figure.